Pathfinder Medical, based in London, aims to revolutionize kidney failure treatment with its novel catheter system for haemodialysis. Unlike traditional catheters and fistulas that often lead to complications and discomfort, Pathfinder's approach promises greater efficiency and enhanced patient comfort. This positions the company to fill a significant gap in the healthcare market. Backed by investors like the Business Growth Fund, Deepbridge Capital, and Parkwalk Advisors, Pathfinder has strong financial support for development and commercialization. Its B2B model, targeting healthcare providers and institutions, ensures a focused and scalable pathway for growth. With its potential to improve patient outcomes, Pathfinder stands poised for long-term success.